Supporting the evidence outlined in our case regarding the effectiveness of targeted Trk-inhibition therapy, another case reported in the literature describes a patient with NTRK fusion-positive cervical sarcoma. This evidence concerns the gene TPM3 and sarcoma of cervix uteri.